Biogen nabs approval of subcutaneous version of Leqembi for initiation dose
Seeking Alpha ·
The US FDA has approved Biogen ( BIIB ) and Eisai's ( ESALF ) ( ESAIY ) Leqembi Iqlik (lecanemab), a subcutaneous version of its Alzheimer's treatment Leqembi, that can be administered for initiation and maintenance dosing, as well as at-home use.
AI 시장 분석
The biotech sector is expected to have a positive impact. The US FDA has approved the subcutaneous version of Leqembi, a treatment for Alzheimer's, called Leqembi Iqliq.
상승 영향
- Biotech — The approval by the US FDA is expected to accelerate the development and sales of Leqembi Iqliq. Additionally, the product's home use will increase treatment accessibility and demand.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 68% · Bearish (Short) 32%
322 participants